for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MediciNova, Inc.

MNOV.O

Latest Trade

2.23USD

Change

-0.02(-0.89%)

Volume

44,826

Today's Range

2.18

 - 

2.28

52 Week Range

2.13

 - 

10.81

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.25
Open
2.22
Volume
44,826
3M AVG Volume
11.02
Today's High
2.28
Today's Low
2.18
52 Week High
10.81
52 Week Low
2.13
Shares Out (MIL)
49.04
Market Cap (MIL)
116.23
Forward P/E
-8.89
Dividend (Yield %)
--

Next Event

Q4 2021 MediciNova Inc Earnings Release

Latest Developments

More

MediciNova Says Effective July 31, 2021, Edward Stepanow Resigned As CFO

Medicinova Announces Positive Results From Phase 2 Trial Of Mn-166 (Ibudilast) In Alcohol Use Disorder Published In Nature’S Translational Psychiatry Journal

Medicinova Reports First Quarter 2021 Financial Results And Business Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MediciNova, Inc.

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focused on the United States market. It is currently focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). ibudilast is developing for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), and prevention of acute respiratory distress syndrome. tipelukast is developing for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 for solid tumor cancers.

Industry

Biotechnology & Drugs

Contact Info

4275 Executive Sq Ste 300

LA JOLLA, CA

92037-8408

United States

+1.858.3731500

https://medicinova.com/

Executive Leadership

Jeffrey Himawan

Independent Chairman of the Board

Yuichi Iwaki

President, Chief Executive Officer, Director

Douglas Paulin

Chief Financial Officer, Principal Financial Officer

Geoffrey G. O'brien

Vice President

Kazuko Matsuda

Chief Medical Officer, Director

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.360

2019

-0.300

2020

-0.300

2021(E)

-0.267
Price To Earnings (TTM)
--
Price To Sales (TTM)
28.79
Price To Book (MRQ)
1.34
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-13.55
Return on Equity (TTM)
-13.07

Latest News

Latest News

BRIEF-Medicinova Inc - IND For Ibudilast Has Been Accepted And Is Now Open With FDA

* MEDICINOVA INC - IND) FOR MN-166 (IBUDILAST) FOR PREVENTION OF ACUTE RESPIRATORY DISTRESS SYNDROME HAS BEEN ACCEPTED AND IS NOW OPEN WITH FDA

BRIEF-Medicinova Announces Positive Preclinical Results Of Mn-166 In Glioblastoma Published In Frontiers In Immunology

* MEDICINOVA ANNOUNCES POSITIVE PRECLINICAL RESULTS REGARDING MN-166 (IBUDILAST) IN GLIOBLASTOMA (GBM) PUBLISHED IN FRONTIERS IN IMMUNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Medicinova Announces Plans To Initiate A Clinical Trial Of Mn-166 For Covid-19 Acute Respiratory Distress Syndrome

* MEDICINOVA ANNOUNCES PLANS TO INITIATE A CLINICAL TRIAL OF MN-166 (IBUDILAST) FOR COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Medicinova Plans To Start MN-166 Development For Severe Pneumonia And Acute Respiratory Distress Syndrome

* PLANS TO INITIATE DEVELOPMENT OF MN-166 (IBUDILAST) FOR SEVERE PNEUMONIA AND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). Source text for Eikon: Further company coverage:

BRIEF-Medicinova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For Treatment Of Advanced NASH In Japan

* MEDICINOVA RECEIVES NOTICE OF ALLOWANCE FOR NEW PATENT COVERING MN-001 AND MN-002 FOR THE TREATMENT OF ADVANCED NASH IN JAPAN

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up